Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials
Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality …
Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
AJ Scheen - Circulation research, 2018 - Am Heart Assoc
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …